LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2receptor-Reference-Cited by-同舟云学术

LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2receptor

Published:1998-09 Issue:2 Volume:125 Page:365-372
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:

Author:

Pruneau Didier,Luccarini Jean-Michel,Fouchet Chantal,Defrêne Evelyne,Franck Rose-Marie,Loillier Bruno,Duclos Hervé,Robert Claude,Cremers Béatrice,Bélichard Pierre,Paquet Jean-Luc

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/sj.bjp.0702083/fullpdf

Reference50 articles.

1. Characterization of the capsaicin-sensitive component of cyclophosphamide-induced inflamMation in the rat urinary bladder;Ahluwalia;Br. J. Pharmacol.,1994

2. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma;Akbary;ImMunopharmacology,1996

3. Novel subtype-selective nonpeptide bradykinin receptor antagonists Fr167344 and Fr173657;Aramori;Mol. Pharmacol.,1997

4. The idendification of an orally active, nonpeptide bradykinin B2 receptor antagonist, Fr173657;Asano;Br. J. Pharmacol.,1997

5. Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage;Austin;Br. J. Pharmacol.,1994

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development;International Immunopharmacology;2022-04

2. In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist;Frontiers in Pharmacology;2020-06-19

3. New insights into the stereochemical requirements of the bradykinin B2 receptor antagonists binding;Journal of Computer-Aided Molecular Design;2015-12-24

4. Therapeutic window of bradykinin B2 receptor inhibition after focal cerebral ischemia in rats;Neurochemistry International;2006-10

5. Sesamin Metabolites Induce an Endothelial Nitric Oxide-Dependent Vasorelaxation through Their Antioxidative Property-Independent Mechanisms: Possible Involvement of the Metabolites in the Antihypertensive Effect of Sesamin;Journal of Pharmacology and Experimental Therapeutics;2006-04-05